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individuals during 2004-2008 were used in this retrospective database study of
patients with metastatic or recurrent, locally-advanced HNC. Patients diagnosed
with HNCwerematched 1:1 to cancer-free control patients in order tomeasure the
incremental economic burden of metastatic and recurrent, locally-advanced HNC.
Outcomes of interest were measured during the 6 months following 1) date of a
secondary tumor diagnosis for metastatic patients, or 2) date of a diagnosis indi-
cating recurrent, locally-advanced HNC. The multivariable comparison of health-
care utilization rates was based on a logistic regressionmodel. Costs were reported
in 2008 US dollars from the perspective of a third-party payer and were analyzed
using generalized linear models and two-part regressionmodels. Regressionmod-
els were adjusted for age and baseline Charlson Comorbidity Index (excluding
cancer diagnoses) differences between HNC and control patients. RESULTS: The
metastatic HNC cohort consisted of 1,042 patients; the cohort of recurrent, locally-
advanced HNC included 324 patients. Compared to cancer-free patients, a higher
proportion of metastatic HNC patients had  1claim for inpatient (OR26.4), out-
patient (OR35.3), and ER visits (OR4.4). Recurrent, locally-advanced HNC pa-
tients also hadhigher utilization rates for inpatient (OR4.7) and ER visits (OR4.9).
All differences were statistically significant (p0.0001). Incremental adjusted total
costs were $60,414 per patient for metastatic HNC and $21,141 per patient for
recurrent, locally-advanced HNC (p0.0001). Approximately 46-58% of the incre-
mental cost was attributable to outpatient visits, 27-37% to inpatient costs, and
11-13% to pharmacy, depending on the cohort. CONCLUSIONS: Healthcare re-
source utilization and economic burden of patients with metastatic or recurrent,
locally-advanced HNC is substantial compared to cancer-free patients.
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HEALTH CARE VISITS
Hill J1, Shreay S2, McGarvey N2, De AP1, Hess GP1, Corey-Lisle P2
1SDI Health, Plymouth Meeting, PA, USA, 2Amgen, Inc., Thousand Oaks, CA, USA
OBJECTIVES: Dosing schedules for the erythropoiesis-stimulating agents (ESAs),
darbepoetin alfa (DA) and epoetin alfa (EA), differ with the availability of Q3W
dosing for DA compared to the predominantly weekly schedule for EA. For chemo-
therapy regimens with longer intervals between administrations, DA can be ad-
ministered less frequently than EA and presumably with a higher likelihood of
synchronization between chemotherapy and ESA schedules. This study examined
frequency of ESA visits and synchronization of chemotherapy and ESA adminis-
trations in current clinical practice. METHODS: A retrospective analysis of ESAs
utilization during ESA Episodes of Care (ESA EOCs) was conducted on all cancer
patients undergoing chemotherapy and receiving ESA therapy between 7/1/2007 to
3/31/2010 (n9,961). Patientswere identified in the SDI oncology electronicmedical
records database. ESA administrations were classified as synchronized with che-
motherapy-i.e. either received on the same day-or unsynchronized. The odds that
an ESA visit was synchronized with chemotherapy was compared for patients
receiving DA and EA using generalized estimating equations (GEE). Mean health-
care visits were compared usingHeckman’s 2-step estimator to overcome the sam-
ple selection bias. RESULTS: The numbers of patients by ESAwere 6,522 for DA and
3,439 for EA. The overall synchronization was higher for the DA (DA67% &
EA58%; p0.0001). The odds that an ESA administration was synchronized with
chemotherapy was higher for DA compared to EA (OR1.46, 95%CI: 1.37-1.54). DA
patients had 2.3 fewer visits with an ESA administration (p0.0001), and 3.0 fewer
total visits over the ESA EOC (p0.0001). CONCLUSIONS: Patients receiving DA
were more likely to have an ESA administration on the same healthcare visit as
chemotherapy and had fewer visits for ESA administrations compared to EA. This
evidence suggests that DAmay reduce patient and practice burden through greater
synchronization of ESA and chemotherapy administrations andmay reduce health
care utilization compared to EA.
PCN103
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PERSPECTIVE
Chadda S1, Larkin M1, Jones C1, Sykes D1, Barber B2, Zhao Z2, Gao S2, Bengttson NO3
1PRMA Consulting, Fleet, UK, 2Amgen, Inc., Thousand Oaks, CA, USA, 3Norrlands
Universitetssjukhus, Umeå, Sweden
OBJECTIVES:Monoclonal antibody (mAb) therapies for the treatment ofmetastatic
colorectal cancer (mCRC) are associated with a risk of infusion reactions, though
the rates of infusion reactions differ among mAbs. Currently there is limited pub-
lished data on the clinical and economic impact of infusion reactions. The objective
of this studywas to investigate the resource use associatedwith infusion reactions
and the impact of these reactions on patient management in real-world clinical
practice in Europe.METHODS: Eighty oncologists and nurses from eight European
countries (Denmark, France, Germany, Greece, Italy, Spain, Sweden and the UK)
were interviewed by telephone over a 6-week period in 2010. To be included, the
respondents (10 from each country) must be currently treating patients with
mCRC. Each telephone interview lasted 30-45 minutes using a questionnaire (16
questions) specifically developed for this study. RESULTS: The mean number of
total staff (including physicians and nurses) involved in managing an infusion
reactionwas 1.97 for a grade 1 infusion reaction, 2.35 for a grade 2 infusion reaction,
3.60 for a grade 3 infusion reaction and 5.30 for a grade 4 infusion reaction. For
grade 3 infusion reactions, the majority of patients (73.4%) were treated in a hos-
pital inpatient setting; while for grade 4 infusion reactions, themajority of patients
(82.5%) were treated in intensive care. Treatment duration in hospitals for infusion
reactions also increased with the severity. Among patients hospitalized for infu-
sion reactions, grade 3 infusion reactions were treated for a mean of half day (13.3
( 29) hours) in intensive care compared to amean of 2 days (48.1 ( 43.7) hours) for
grade 4 infusion reactions. CONCLUSIONS: In conclusion, infusion reactions led to
substantial resource use, which increased with the severity of the infusion reac-
tions in real-world clinical practice across eight European countries.
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OBJECTIVES: Monoclonal antibody treatments for metastatic colorectal cancer
(mCRC) have different treatment-related toxicities. This study aimed to elucidate
the hospitalisation costs of adverse events (AEs) commonly associated withmono-
clonal antibodies when administered to patients with mCRC. METHODS: This
study extracted data for patients newly diagnosed with mCRC from a large US
claims database from January 2005 to June 2008. The first distant metastasis diag-
nosis date was defined as the index date. Hospital admissions for AEs of interest
were identified by primary discharge diagnoses after the index date. Main out-
comes weremean length of hospital stay (days) and hospitalisation costs (US$) per
hospital admission for AEs identified. All analyses are presented descriptively.
RESULTS: The study population (aged 18 years; n12,648) was balanced accord-
ing to gender and was mainly aged 50 years or older (90.1%). Most patients had
colon cancer (70.1%) as opposed to rectal cancer. The longestmean (median) length
of stay was observed forWound-healing complications (14.1 (7.0) days) and gastro-
intestinal (GI) perforation (13.8 (11.5) days), followed by hypertension (8.5 (3.0)
days), arterial thromboembolism (7.1 (5.5) days), venous thromboembolism (5.4
(4.0) days), and congestive heart failure (5.3 (4.0) days). The highest inpatient cost
per event was for GI perforations (mean $66,224 and median $34,027), followed by
arterial thromboembolism (mean $40,992 and median $18,587), wound-healing
complications (mean $36,440 and median $21,163), interstitial lung disease (mean
$26,705 and median $19,111), and acute myocardial infarction (mean $22,395 and
median $15,223). Skin toxicity (mean $6,475 and median $6110) was associated
with relatively low costs. CONCLUSIONS: Hospital costs for monoclonal antibody
treatment-related AEs in patients with mCRC vary greatly. This study provides
source data for economic evaluations of head-to-head comparisons of monoclonal
antibody treatments.
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OBJECTIVES: To estimate NICE’s cost effectiveness threshold following application
of its end-of-life supplemental advice criteria (EOL) to single technology appraisals
(STA) for cancer drugs.METHODS:We searched all NICE STAs for cancer drugs in
2009 and 2010 and identified 30 STAs for which EOL advice was given.We excluded
two STAs because the estimated ICER was less than NICE’s cost effectiveness
threshold value of £30,000. Each STA was evaluated on the extent to which NICE
deemed the drug to have satisfied each of the three EOL criteria. The ICER of each
drug that met all three EOL criteria was compared to the £30,000 threshold.
RESULTS: Two of the 28 drugs did not meet the first criterion that the treatment is
indicated for patients whose life expectancy is normally less than 24 months. Twelve drugs
did not meet the second criterion that there is sufficient evidence to indicate that the tech-
nology extends life by at least 3 months compared to current NHS treatments. Eight drugs
did not meet the third criterion that the treatment is indicated for small patient populations.
Four STAs only evaluated two of the three EOL criteria. In all, Appraisal Committees
considered 14 drugs to have satisfied the three EOL criteria, only six of which were
considered cost effective. The highest ICER for cost effective treatments was £47,000
and the lowest ICERwas £52,600 for the eight treatmentsnot considered cost effective.
CONCLUSIONS: It can be reasonably surmised that the cost effectiveness threshold
for EOL treatments is around £50,000. How EOL criteria are interpreted varies, how-
ever. The first criterion is straightforward, based largely onwidely accepted estimates
of life expectancy for the given indication. Robustness of survival data will dictate
application of the second criterion. Manufacturers should expect an estimated popu-
lation of 7,000 to satisfy the third criterion.
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OBJECTIVES: Taking stapler as an example, to explore the factors affection the
adoption of high value medical consumes in less developed areas of China.
METHODS: 714 medical records were selected from the prefecture-level and cou-
nty-level hospitals in Hubei, Henan, Sichuan and Shandong to collect information
and 117 relevant personnel were interviewed deeply. RESULTS: Drivers and Barri-
ers for Stapler Adoption Drivers: Strong perceived benefits and cost-effectiveness
among surgeons, hospital leaders; Hospitals and surgeons keen to adopt new tech-
nologies and techniques; General market development. Barriers: Prefecture Level:
No significant barrier to adoption; key issue is market share versus domestic; bar-
riers to share gain are surgeon loyalty to and moderate satisfaction with domestic
products, reimbursement policy. County Level: Patient affordability and surgeon
skills/awareness are both barriers, but our study design did not permit quantifica-
tion of their relative impacts. Decision-Making Unit and Influences: Surgical direc-
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tor and hospital dean are usually key people pushing for stapler adoption; patients
typically follow surgeon’s advice about stapler; procurement and other hospital
departments have more limited roles; Reimbursement: Stapler is generally reim-
bursed by urban health insurance programs but not by New Rural Cooperative
Medical System (NRCMS). Main concern of NRCMS authorities is maintaining fund
balance; formal Cost Effectiveness Analysis is not presently used by NRCMS au-
thorities. Pilot Cost Effectiveness Analysis Retrospective pilot cost effectiveness
analysis did not broadly demonstrate statistically significant favorable evidence for
stapler. CONCLUSIONS: Doctors’ operation skills should be trained, cost effective-
ness analysis should be continued, as well as the basic medical security system
should be improved in China.
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OBJECTIVES: To assess the payer-rated value of improved pain response, reduced
analgesic medication use and increased overall survival treatment benefit, for pa-
tients with castration-resistant prostate cancer (CRPC).METHODS:We used a con-
venience sample of payers in the US, France and Italy to conduct a telephone
surveywith an accompanyingweb-based questionnaire. The concern of the survey
was the value to payers of a clinically significant pain response. The web-based
questionnaire included nine different treatment/outcome scenarios associated
with adding a second-generation antisense oligonucleotide (ASO) (product X) to
standard of care (SOC) for patients with CRPC. Scenarios varied in terms of the
percentage of patients who experienced a significant pain response with a concur-
rent specified reduction in pain medication use and survival benefit. For each sce-
nario, the respondents rated their likelihood to recommend product X on a scale
ranged from 1 (definitely would not) through 4 (definitely would). We analyzed quan-
titative scenario responses through use of linear regression methods; qualitative
data analysis was limited to simple item summaries. RESULTS:A total of 36 payers
in the U.S., France and Italy completed the survey and questionnaire. The qualita-
tive data from all three regions showed improved survival drove affirmative rec-
ommendations for product X added to SOC. Informants from France and Italy also
consistently ranked improved pain response as an important product attribute.
The informants also said they would like more evidence regarding cost offsets
associated with the improved pain response of product X plus SOC. The regression
modeling was consistent with the qualitative observations. CONCLUSIONS: Cov-
erage recommendations for the medical management of CRPC are primarily based
on the amount of overall survival treatment benefit. In addition, most payers rec-
ognize increased pain response as an important attribute and said evidence of the
cost offsets associated with pain response would aid decision making.
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OBJECTIVES: Overall Survival (OS) has generally been considered the “gold stan-
dard endpoint” for cancer therapies as it can be assessed with precise accuracy.
Due to long follow up periods, however, crossover effects, subsequent therapies
and large trial sizes, OS is becoming a less feasible endpoint. Therefore, there has
been a shift towards the acceptance of surrogate endpoints as determinants of
clinical efficacy for cancer therapies. In Canada, the iJODR conducts health tech-
nology assessments for oncology products and provides funding recommenda-
tions to public payers. This study was conducted to determine the significance of
various endpoints on decision-making by the iJODR.METHODS: Public recommen-
dations of 23 oncology drugs by the iJODR betweenMarch 2007 and December 2010
were reviewed. Recommendations were analyzed according to therapy setting,
primary and secondary endpoints and clinical results. RESULTS: Of the 23 submis-
sions, one was for use in the adjuvant setting, measuring Disease Free Survival
(DFS) as its primary endpoint and received a positive recommendation. Of the 22
drugs indicated for advanced/metastatic disease, primary endpoints were mea-
sured in 12 (55%) through OS, 5 (18%) through Progression Free Survival (PFS) and 6
(27%) through either Response Rates (RR) or Time to Progression (TTP). Secondary
endpoints included OS, PFS, toxicity, RR, TTP, Quality of Life or Rate of Progression.
Of the 12 drugs with OS as a primary endpoint, 7 (58%) showed statistically signif-
icant increases in OS, with 4 (57%) granted a positive recommendation. Of the 5
with no statistically significant OS improvement, 3 (60%) received positive recom-
mendations based on secondary endpoints. Of the 10 drugswith surrogate primary
endpoints, 6 (60%) received positive recommendations. CONCLUSIONS: These
findings suggest that surrogate endpoints are becoming more commonly used in
clinical trials for regulatory approval and accepted as true measures of clinical
efficacy for oncology therapies in Canada’s funding decisions.
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OBJECTIVES: This study describes the real-world healthcare resource utilization
patterns for MPC patients treated by a urologist and/or an oncologist versus urol-
ogist only. METHODS: Health insurance claims (01/1999-02/2009) from 40 self-in-
sured companies across the US were analyzed. Patients with a metastasis diagno-
sis (ICD-9: 196-199) following 2 prostate cancer diagnoses (ICD-9: 185, V10.46)
within 365 days were identified. Patients with other malignant diagnoses were
excluded. Patients were categorized in the ONCO group if they had 1 claim from
an oncologist ( claims from urologist) and the URO group if they had claims only
from urologist (i.e., no claim from an oncologist). Patients were evaluated for che-
motherapy, hormonal agents, corticosteroids, supportive care, and hospitaliza-
tions during both baseline (defined as 365 days prior tometastasis diagnosis [index
date]) and observation periods. RESULTS: A total of 1,661 URO and 1,131 ONCO
patients formed the study population. At baseline, mean age was similar for URO
and ONCO patients (72.3 vs. 72.8 years). During the baseline period, fewer URO
patients received chemotherapy (3.8% vs. 7.3%), hormonal agents (45.1% vs. 63.1%),
and corticosteroids (16.6%vs. 26.5%), compared to theONCOgroup. The same trend
was observed for supportive care therapies (URO vs. ONCO; biphosphonates: 4.8%
vs. 10.5%; opioids: 33.4% vs. 41.8%). The rate of hospitalization at baseline was
similar between groups. During the observation period, 13.4% of URO patients re-
ceived chemotherapy, compared to 38.5% for ONCO patients. Similar differences
were observed for the use of hormonal therapy (52.7% vs. 71.3%), corticosteroids
(36.5% vs. 61.9%), and supportive care therapies (biphosphonates: 18.1% vs. 38.7%;
opioids: 58.7% vs. 68.3%). Fewer URO patients had hospitalizations (62.4% vs. 72.8%)
during the observation period. CONCLUSIONS: The findings from this observa-
tional study may contribute to the understanding of differing healthcare resource
utilization patterns by physician specialty.
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OBJECTIVES: In metastatic prostate cancer (MPC) patients, treatment options in-
clude hormonal therapies, chemotherapy, and radiotherapy. This study quantifies
the real-world healthcare resource utilization of MPC patients.METHODS: Health
insurance claims from 40 self-insured companies across the US (Employer [E]; 01/
1999-02/2009), and from theMedicare 5% ([M]; 1999-2008) databaseswere analyzed.
Patients with a metastasis diagnosis (ICD-9: 196-199) following 2 prostate cancer
diagnoses (ICD-9: 185, V10.46) within 365 days were identified. Patients with other
malignant diagnoses at baseline, defined as 365 days prior to metastasis diagnosis
(index date), were excluded. Patients were evaluated for baseline medical history,
and for chemotherapy, hormonal agents, radiation, and corticosteroids utilization
during both baseline and observation periods. Hospitalization rates and prostate
cancer-related procedures post index datewere also reported. RESULTS: The study
population comprised 11,725 patients (E: 3,227; M: 8,498). Mean age (SD) was 72.8
(10.2) in Employer and 78.1 (7.7) in Medicare. Mean observation period (SD) was 803
(753) days in Employer and 9.2 (8.2) quarters in Medicare. During the baseline pe-
riod, chemotherapy, hormonal agents, radiation therapy, and corticosteroids were
administered to 5%, 52%, 9%, and 21% of Employer, and 2%, 45%, 8%, and 12% of
Medicare patients respectively, whereas these interventions increased to 22%, 55%,
39%, and 46% for Employer, and to 21%, 50%, 33%, and 29% for Medicare during the
observation period. A total of 66% Employer and 79% Medicare patients were hos-
pitalized post index date. Most patients (E: 92%; M: 98%) had prostate cancer-re-
lated procedures, including prostate specific-antigen testing (E: 39%; M: 80%), com-
puterized axial tomography scan (E: 72%; M: 81%), prostate biopsy (E: 47%; M: 54%),
X-ray (E: 11%;M: 64%), bone scan (E: 56%;M: 60%), andmagnetic resonance imaging
scan (E: 35%; M: 37%). CONCLUSIONS: This observational study describes real-
world utilization patterns in patients with advanced prostate cancer.
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OBJECTIVES: Themain objective is to define clusters of patient diagnoses and to use
them to analyze breast cancer health outcomes.METHODS: The NIS records of 2005
were used. Patients diagnosedwith breast cancerwere extracted, and then clusters of
strings of all diagnoses per hospitalization were defined. Logistic regression models
were used to determine the risk of dying from hospitalization associated with each
cluster and ANOVA models were used to evaluate the effect of diagnosis clusters on
length of stay. Time series models were used to fit the data and predict onemonth of
total charges and the number of hospitalizations for each cluster. The analysis was
performed with SAS, SAS Enterprise Guide (EG), SAS Enterprise Miner (EM), and the
SAS Time Series Forecasting System. RESULTS: Four clusterswere found. These clus-
ters had a significant effect on length of stay and in-hospital death. The best time
seriesmodelswere found to be themean, linear trendand log linear trend. The cluster
defined by breast cancer with internal body organ failure was found to be the worst
conditionwith a longer in-hospital stay and ahigher risk of in-hospital death. The one
month predicted values for this cluster were found to be 942 hospitalizations and
about $26million in total charges.CONCLUSIONS:Cluster analysis is a usefulmethod
to studyhealthoutcomes. EnterpriseMiner is aneffective software for cluster analysis
and Data Mining in general.
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